DARVIAS darinaparsin
Drug Class
Organoarsenical compound有机砷化合物
Mechanism
Disrupts mitochondrial function and increases intracellular reactive oxygen species (ROS), causing apoptosis in tumor cells.干扰线粒体功能并增加细胞内活性氧 (ROS)，从而诱导肿瘤细胞发生凋亡。
Approved Indication
Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).用于治疗复发或难治性外周 T 细胞淋巴瘤 (PTCL) 患者。
What This Means For Patients
Darvias (darinaparsin) is an organic arsenic-derived oncology drug approved in Japan for peripheral T-cell lymphoma. It operates by disrupting cellular energy production within cancer cells to trigger their cell death. It is available under the special-import policy in the Hainan Boao Lecheng pilot zone.Darvias（达利帕辛）是在日本获批治疗外周 T 细胞淋巴瘤的一种有机砷类抗肿瘤药物。它通过破坏癌细胞内部的能量产生来诱导细胞死亡。该药物已通过先行区特许进口政策引入博鳌乐城。
Regulatory Approvals
- PMDA — approved (2022) — source
Pivotal Clinical Evidence
- Asian Phase 2 Study — Kim et al., Blood Adv 2023 (NCT02653976) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.